FDA 483 - Boston Scientific Corporation - January 11, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Boston Scientific Corporation in Fremont, CA, revealed significant quality system deficiencies related to their Angiolet Thrombectomy System. The firm failed to report device corrections to the FDA, adequately establish corrective and preventive action procedures, and properly investigate complaints regarding device malfunctions. These issues primarily concerned sticking foot pedals, indicating a lack of robust quality control and potential risks to patient safety.
ID · 941df74c-8d96-4cf9-9b26-0fe623c650e1